Login / Signup

Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE.

Kerry A CaseyXiang GuoMichael A SmithShiliang WangDominic SinibaldiMiguel A SanjuanLiangwei WangGabor G IlleiWendy I White
Published in: Lupus science & medicine (2018)
NCT01438489.
Keyphrases
  • immune response
  • systemic lupus erythematosus
  • dendritic cells
  • disease activity
  • binding protein
  • rheumatoid arthritis